Chronic mucormycosis manifesting as hydrocephalus

Sir; Fungal infections of the brain usually present as chronic meningitis. Mucormycosis of the brain, however, typically presents as acute rhinocerebral disease and is fatal.¹ A search of the English literature revealed only three cases of chronic meningitis due to mucormycosis. All had rhinocerebral involvement and underlying metabolic disease.^{2,3} Fungal meningitis presenting primarily as hydrocephalus is rare. We here report such a patient. There were three uncommon features: (1) The primary presentation as hydrocephalus, (2) The presence of chronic basal meningitis without rhinocerebral involvement, (3) The occurrence in an immunocompetent host.

A 22-year-old female was admitted to hospital on 5 January, 1984 with complaints of convulsions, vomiting and headache of three months duration together with diplopia and unsteadiness for 15 days. She denied fever, cough, expectoration, pain in the neck or discharge from the ears. She was conscious and oriented. The pulse rate was 50/min, the BP 140/80 mm Hg and respiratory rate 30/min. There was bilateral papilloedema. The cranial nerves and the motor and sensory systems were normal. The tendon reflexes were all present and the plantar responses were extensor. Brudzinski and Kernig signs were negative. There was bilateral incoordination of the limbs, trunkal ataxia and nystagmus. Romberg's sign was negative. Examination of the abdomen and the cardiovascular and respiratory system did not reveal any abnormality. The possibility of an intracranial space occupying lesion with raised intracranial pressure was entertained. The bilateral cerebellar deficit was considered to be a false localising sign.

Investigations revealed Hb 12 g%, total white count 6900/cmm, differential leucocyte count: polymorphs 50%, lymphocytes 42% and eosinophils 8% and ESR 77 mm in the first hour. Blood sugar was 108 mg/dl fasting and post prandial 120 mg/dl. The blood urea, creatinine level and liver function tests were within normal limits. The chest radiograph was normal but radiographs of the skull revealed osteoporosis of the posterior clinoid processes. A CT scan showed hydrocephalus.

Lumbar puncture was not performed because of papilloedema and the absence of signs of meningeal irritation. The patient was put on anticonvulsants and mannitol. After the report of the CT had been

received, steroids and antituberculous therapy were started. The patient deteriorated and died on 22 January 1984 from cardiorespiratory arrest following presumed tonsillar herniation.

At necropsy the brain was oedematous and weighed 1200 g. There was bilateral tonsillar herniation. The basal meninges were thickened and pearly white in colour. Whitish gelatinous exudate was seen filling the basal cisterns and covering the front of the pons and medulla. The cranial nerves and the basal vessels were entangled in the exudate. Sections revealed dilated lateral ventricles whose walls were smooth. There were no infarcts or abscesses in the brain substance. Microscopically the brain showed granulomatous lesions consisting of giant cells and epithelioid cells with necrotic centres containing fungi with broad non-septate hyphae. Sections from the nose and sinuses did not show evidence of necrosis or mucormycosis. A methanamine silver stain of brain confirmed that infection was mucormycosis. Gomori methanamine silver stains all forms of fungi black. Mucormycosis shows broad non-septate hyphae. The diameter of these hyphae is 10–15 μ , which differentiates them from *Aspergillus*, whose hyphae are septate and of 3–4 μ in diameter. The uniform dichotomous pattern of branching of hyphae in tissues also helps to differentiate *Aspergillus* from mucormycosis.⁴

Rhinocerebral mucormycosis usually presents as acute meningitis, meningo-encephalitis or cerebral abscess. Only three cases of chronic mucormycosis have so far been reported. These presented with typical sinus and rhinocerebral involvement and histologically showed chronic granulomatous inflammation.^{2,3} All had underlying metabolic disease. Our patient, however, had no such underlying illness. The history of convulsions, headache and vomiting suggested a space occupying lesion. The CT scan, however, only revealed hydrocephalus. In India tuberculous meningitis is the commonest cause of acquired hydrocephalus and our patient was given anti-tuberculous treatment.⁵ Of four reported patients with fungal meningitis, primarily presenting as hydrocephalus, three had cryptococcal infection and one had aspergillosis.⁶ The diagnosis especially of cryptococcosis has become easier, but the diagnosis of mucormycosis remains notoriously difficult owing to the altered haemodynamics of CSF flow following basal meningitis and the fact that the CSF is nearly always devoid of the relevant organisms. Our patient died before any shunt

operation could be performed. The conclusion would seem to be that fungal infection should be excluded in all patients with hydrocephalus of unknown aetiology before shunt operations are undertaken.

LATA S BICHILE
SHASHIKALA C ABHYANKAR
N K HASE

Departments of Medicine and Pathology,
Lokmanya Tilak Municipal Medical College and Hospital,
Sion, Bombay 400 022.
India.

References

- Emmons CW, Binford CH, Utz JP, Chung KJ. *Medical Mycology*, 3rd ed., Philadelphia, Lea and Febiger, 1977:254–82.
- Julian EF, Cohen SH, Harold DR, Rytal MW. Chronic rhinocerebral phycomycosis in association with diabetes. *Post Grad Med J* 1977;53:337–42.
- Helderman JH, Cooper HS, Mann J. Chronic phycomycosis in a controlled diabetic. *Ann Int Med* 1974;80:419–21.
- Emmons CW, Binford CH, Utz JP, Kwan Chung KJ. *Medical Mycology*, 3rd ed., Philadelphia, Lea and Febiger, 1977:58–59.
- Udani PM, Parekh UC, Dastur DK. Neurological and related syndromes in CNS tuberculosis. *J Neurol Sc* 1971;14:431–57.
- Deborah M, Gerding DN, Peterson LR, Sarosis GA. Fungal meningitis manifesting as hydrocephalus. *Arch Int Med* 1983;143:728–31.

Impaired neurotransmitter amine metabolism in arginase deficiency

Sir: Arginase deficiency, an inborn error of the urea cycle leading to accumulation of arginine, causes a severe progressive neurodegenerative disorder characterised by mental retardation and a spastic diplegia.^{1,2} The mechanisms responsible for the neurological damage are uncertain. It is unlikely to be due to hyperammonaemia alone since only moderate ammonia accumulation occurs in this disorder which more closely resembles an amino-acidopathy such as phenylketonuria than the other urea cycle disorders.² In a patient with arginase deficiency we have recently observed a disturbance of cerebrospinal fluid (CSF) catecholamine and serotonin metabolism similar to that in patients with "classical" phenylketonuria. The findings are consistent with the view that inhibition of aminoacid uptake by the brain is a com-

mon factor in the pathogenesis of neurological damage in these two disorders.

An 11 yr-old-girl with arginase deficiency (confirmed by enzyme assay by Prof AD Patrick) was investigated before and after the start of treatment. She was severely retarded and inert with unintelligible speech. On neurological examination she had a pseudobulbar palsy and a spastic quadriplegia. Plasma and cerebrospinal fluid (CSF) arginine concentrations were markedly elevated (table). CSF concentrations of homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) (table), the major metabolites of dopamine and serotonin respectively were low, 5HIAA markedly so. These rose as plasma and CSF arginine fell when she was started on a low protein diet with supplements of essential aminoacids and sodium benzoate. Subsequently amine metabolite concentrations fell as arginine concentrations rose once again owing to difficulties with the diet.

The pattern of amine metabolite changes, including the greater initial reduction of CSF 5HIAA concentrations compared to those of HVA, resemble closely the pattern seen in two patients with classical phenylketonuria (table) who were investigated after they had developed neurological symptoms following withdrawal of the low phenylalanine diet. The profound reduction of 5HIAA in the presence of hyperarginaemia contrasts with the findings in patients with ornithine carbamoyl transferase deficiency, another urea cycle disorder, in whom 5HIAA rises

in association with hyperammonaemia due to increased transport of tryptophan into the brain.³

Competition between phenylalanine and the other neutral aminoacids for transport across the blood brain barrier probably accounts for the low concentrations of tryptophan and tyrosine found in the brain of patients with phenylketonuria post mortem.⁴ The hydroxylation of tyrosine to dopa and tryptophan to 5-hydroxytryptophan are the rate-limiting steps in the synthesis of dopamine and serotonin and there is evidence that the rate of hydroxylation of tryptophan, and to a lesser extent tyrosine, is normally regulated by substrate concentrations.^{5,6} Lowered intraneuronal concentrations of these two aminoacids could therefore reduce the rate of amine synthesis. Defective protein synthesis is another consequence of impaired aminoacid transport into the brain⁷ and here too tryptophan deficiency appears to be of special importance.⁸

The changes in amine metabolite concentrations in our patient with hyperarginaemia imply therefore that competition for entry into neurons also occurs between arginine and neutral aminoacids with consequences for protein synthesis as well as amine metabolites. Although the dibasic aminoacids are generally thought to have a separate carrier it has been shown previously that phenylalanine in excess inhibits the transport of arginine and ornithine in brain slices.⁹ Hence the clinical similarities between classical phenylketonuria and arginase deficiency are likely to reflect

common factors in the pathogenesis of neurological damage.

K HYLAND
ISABEL SMITH
PT CLAYTON
JV LEONARD

*Institute of Child Health
and The Hospital for Sick Children,
Great Ormond Street,
London WC1N 1EH, UK*

References

- ¹ Walser M. Urea cycle disorders and other hereditary hyperammonaemic syndromes. In: Stanbury JB, Wyngaarden JB, Fredrickson DB, Golstein JL, Brown MS, eds. *The Metabolic Basis of Inherited Disease* 5th ed. New York: McGraw-Hill, 1983:402-38.
- ² Smith I. The treatment of inborn errors of the urea cycle. *Nature* 1981;291:378-80.
- ³ Bachmann C, Colombo JP. Increased tryptophan uptake into the brain in hyperammonaemia. *Life Sci* 1983;33:2417-24.
- ⁴ McKean CM. The effect of high phenylalanine concentrations on the serotonin and catecholamine metabolites in human brain. *Brain Res* 1972;47:469-75.
- ⁵ Kaufman S. Regulatory properties of pterin dependent hydroxylases: variations on a theme. In: Usdin E, Weiner N, Youdim MBH, eds. *Function and Regulation of Monamine Enzymes*. New York: Macmillan, 1981:165-71.
- ⁶ Wurtman RJ, Fernstrom JD. Control of brain synthesis by diet and plasma aminoacids. *Am J Clin Nutr* 1975;28:638-46.
- ⁷ Agrawal HC, Bone AH, Davison AN. Effect of phenylalanine and protein synthesis in the developing rat brain. *Biochem J* 1970;117:325-31.
- ⁸ Sourkes TL. Effect of α -methyltryptophan on tryptophan, 5-hydroxytryptamine and protein metabolism in the brain. In: Aromatic aminoacids in brain. *Ciba Foundation Symposium* 1974;22(new series):361-78.
- ⁹ Neame KD. Phenylalanine as an inhibitor of transport of aminoacids in brain. *Nature* 1961;192:173-4.

Accepted 23 March 1985

Table CSF neurotransmitter amine and aminoacid concentrations and plasma aminoacid concentrations in arginase deficiency and "classical" phenylketonuria before and after treatment

		Pre-treatment	Post-treatment		Normal range
			1 month	6 months	
Arginase deficiency					
CSF					
HVA ($\mu\text{g/l}$)		33.5	59.9	49.8	72-121*
5HIAA ($\mu\text{g/l}$)		5	16.5	13.1	25-40*
Arginine ($\mu\text{mol/l}$)		63	36	56	15-40
Plasma					
Arginine ($\mu\text{mol/l}$)		663	161	501	30-130
Phenylketonuria (patient 1—aged 16 yrs, patient 2—aged 18 yrs)					
CSF					
HVA ($\mu\text{g/l}$)	patient 1	27	75		72-121
	patient 2	38	44		
5HIAA ($\mu\text{g/l}$)	patient 1	4	19		25-40
	patient 2	6	16		
Plasma					
Phenylalanine ($\mu\text{g/l}$)	patient 1	1400	120		30-120
	patient 2	1800	360		

*The range is derived from six retarded children without movement disorder aged 5-12 years.